| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
PRINCETON, N.J.—Bristol-Myers Squibb Co. has announcedresults from a pooled analysis of survival data for 12 studies—consisting of 1,861subjects total—in patients with metastatic or locally advanced or unresectablemelanoma who were treated with Yervoy (ipilimumab) at different doses andregimens. Central to these announced results, the data for which will bepresented at the 2013 European Cancer Congress Sept. 28, is that a plateau inthe survival curve begins at approximately three years, with follow-up of up to10 years in some patients.
 
 
"This pooled analysis reinforces the long-termsurvival data seen in the individual studies and provides additional insightinto the overall survival of metastatic melanoma patients treated with Yervoy,"said Brian Daniels, senior vice president of global development and medical affairs."The durability and consistency of long-term survival observed in this analysisis encouraging as we continue to advance the research and development of ourimmuno-oncology portfolio."
 
 
"In this analysis, approximately 26 percent oftreatment-naïve and 20 percent of previously treated patients were alive atthree years after being treated with an ipilimumab regimen," added Dr. F.Stephen Hodi, of the Department of Medicine of Harvard Medical School and Dana-FarberCancer Institute. "This pooled analysis is encouraging, particularly whenconsidering that metastatic melanoma is one of the most aggressive forms ofcancer and historically, average survival was just six to nine months."
 
 
Safety data were not included in this analysis; however,safety data from the individual studies have been reported. Overall, the typesof adverse events attributed to Yervoy are generally mechanism-related (i.e.immune-based). Yervoy can result in severe and fatal immune-related adversereactions due to T-cell activation and proliferation. In these clinical trials,adverse events associated with Yervoy were managed with protocol-specificguidelines, including the administration of systemic corticosteroids, doseinterruption/discontinuation and/or other immunosuppressants.
 
 
Yervoy, which is a recombinant, human monoclonalantibody, blocks the cytotoxic T- lymphocyte-associated antigen-4 (CTLA-4).CTLA-4 is a negative regulator of T-cell activation. Yervoy binds to CTLA-4 andblocks the interaction of CTLA-4 with its ligands, CD80/CD86. Blockade ofCTLA-4 has been shown to augment T-cell activation and proliferation. The mechanismof action of Yervoy's effect in patients with melanoma is indirect, possiblythrough T-cell mediated anti-tumor immune responses. On March 25, 2011, the U.S.Food and Drug Administration approved Yervoy 3 mg/kg monotherapy for patientswith unresectable or metastatic melanoma. Yervoy is now approved in more than40 countries.
 
 
SOURCE: Bristol-Myers Squibb news release
 

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

GreenCooling

Thermo Scientific™ Centrifuges with GreenCool Technology

Next-generation natural refrigerant cooling system for centrifuges, offering a lower Global Warming Potential and reduced energy consumption.
Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue